Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer ; volume:23 ; number:1 ; day:4 ; month:4 ; year:2023 ; pages:1-10 ; date:12.2023
BMC cancer ; 23, Heft 1 (4.4.2023), 1-10, 12.2023
- Creator
-
Asowed, Mustafa
Elander, Nils O.
Pettersson, Linn
Ekholm, Maria
Papantoniou, Dimitrios
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-023-10780-y
- URN
-
urn:nbn:de:101:1-2023081909163737744744
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Asowed, Mustafa
- Elander, Nils O.
- Pettersson, Linn
- Ekholm, Maria
- Papantoniou, Dimitrios
- SpringerLink (Online service)
Other Objects (12)
The changing landscape of hormonal therapy in castration-resistant prostate cancer
Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Ailanthone: a new potential drug for castration-resistant prostate cancer
Chromogranin A: a useful biomarker in castration-resistant prostate cancer
The changing landscape of hormonal therapy in castration-resistant prostate cancer
Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Ailanthone: a new potential drug for castration-resistant prostate cancer
Chromogranin A: a useful biomarker in castration-resistant prostate cancer
The changing landscape of hormonal therapy in castration-resistant prostate cancer
Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Ailanthone: a new potential drug for castration-resistant prostate cancer